Compare Recursion Pharmaceuticals Inc (RXRX) vs SK Hynix (SKHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SK Hynix — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while SK Hynix trades at $192.57 (market cap $945.90B). The key difference: SK Hynix is far larger — about 508.5× Recursion Pharmaceuticals Inc's market cap, and SK Hynix is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SKHY | |
|---|---|---|
Market Cap | $1.86B | $945.90B |
Sector | Health | Technology |
52-Week High | $6.79 | $198.63 |
52-Week Low | $2.84 | $126.79 |
Enterprise Value | $1.38B | $896.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
SKHY trades at $185.55, up 4.83% today, with strong fundamental performance including 85.62% net income margin and consistent earnings beats. The stock shows neutral technical signals near pivot point $186, with support at $183 and resistance at $189. Recent news highlights SKHY's leadership in AI memory chips with 50% HBM market share and strong demand from AI infrastructure buildout.
Outlook remains positive with 100% analyst buy ratings and $248 consensus price target representing 34% upside. Key risks include memory cycle volatility and competitive pressures, but strong HBM positioning and expanding AI partnerships provide growth catalysts. Revenue growth accelerated to 85.61% profit margin in 2026 trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SK Hynix
SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →
